MB-107

MB-107 is an autologous chimeric antigen receptor (CAR) T-cell therapy targeting CD7, a transmembrane glycoprotein expressed in more than 95% of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) cases. Developed by March Biosciences, the therapy involves the genetic modification of a patient's own T cells to express a CAR that specifically recognizes the CD7 antigen on malignant cells. This targeted approach is designed to treat challenging hematological cancers where CD7 is a prevalent biomarker. MB-107 is currently in early-stage clinical development, representing a strategic expansion of March Biosciences' pipeline in T-cell malignancies.

Other names

CD7-directed CAR T-cell therapyCD-7-directed CAR T-cell therapyCD 7-directed CAR T-cell therapyautologous CD7 CAR-T